What is the Tenofovir disoproxil fumarate?

Tenofovir disoproxil fumarate is almost white crystalline, while it's Molecular Formula is C19H30N5O10P . C4H4O4. almost white crystalline Acyclic phosphonate nucleotide analogue; reverse transcriptase inhibitor. Used as an anti-HIV agent. Antiviral.

What is the CAS number for Tenofovir disoproxil fumarate?

The CAS number of Tenofovir disoproxil fumarate is 202138-50-9.

What is Tenofovir disoproxil fumarate (202138-50-9) used for?

Tenofovir disoproxil is a prodrug of the acyclic nucleoside phosphonate, tenofovir . Tenofovir is converted by cellular enzymes to tenofovir diphosphate, an obligate chain terminator that inhibits the activity of HIV reverse transcriptase and hepatitis B virus polymerase. Due to its rapid intracellular uptake, the anti-HIV activity of tenofovir disoproxil is reportedly >100-fold greater than that of the negatively charged tenofovir in a T cell line and primary blood lymphocytes.InChI:InChI=1/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1

What is the Tenofovir disoproxil fumarate?

Tenofovir disoproxil fumarate is almost white crystalline, while it's Molecular Formula is C19H30N5O10P . C4H4O4. almost white crystalline Acyclic phosphonate nucleotide analogue; reverse transcriptase inhibitor. Used as an anti-HIV agent. Antiviral.

What is the CAS number for Tenofovir disoproxil fumarate?

The CAS number of Tenofovir disoproxil fumarate is 202138-50-9.

What is Tenofovir disoproxil fumarate (202138-50-9) used for?

Tenofovir disoproxil is a prodrug of the acyclic nucleoside phosphonate, tenofovir . Tenofovir is converted by cellular enzymes to tenofovir diphosphate, an obligate chain terminator that inhibits the activity of HIV reverse transcriptase and hepatitis B virus polymerase. Due to its rapid intracellular uptake, the anti-HIV activity of tenofovir disoproxil is reportedly >100-fold greater than that of the negatively charged tenofovir in a T cell line and primary blood lymphocytes.InChI:InChI=1/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1

Product Class

202138-50-9

Product Name：Tenofovir Disoproxil Fumarate
Molecular Formula：C₁₉H₃₀N₅O₁₀P^.C₄H₄O₄
Purity：99%
Molecular Weight：635.522

Inquiry

Product Details:

CasNo： 202138-50-9

Molecular Formula： C₁₉H₃₀N₅O₁₀P^.C₄H₄O₄

Appearance： almost white crystalline

Buy High Quality Tenofovir Disoproxil Fumarate,Wholesale 202138-50-9 Safe Transportation

Molecular Formula:C19H30N5O10P^.C4H4O4
Molecular Weight:635.522
Appearance/Colour:almost white crystalline
Vapor Pressure:2.06E-16mmHg at 25°C
Melting Point:219oC
Boiling Point:642.7 °C at 760 mmHg
Flash Point:342.5 °C
PSA：269.85000
Density:1.45 g/cm³
LogP:3.32860

Tenofovir disoproxil fumarate(Cas 202138-50-9) Usage

Overview	Tenofovir Disoproxil Fumarate is an oral prodrug of tenofovir, which is a nucleotide analogue of adenosine monophosphate. Upon absorption, it is rapidly converted to its active form, tenofovir diphosphate, which inhibits the reverse transcriptase enzyme in retroviruses like HIV, preventing viral replication. It is sold under the brand name Viread.
Uses	Tenofovir Disoproxil Fumarate (TDF) belongs to the category of antiviral drugs. It is specifically classified as a nucleotide reverse transcriptase inhibitor (NRTI) used in the treatment of viral infections, particularly HIV and chronic hepatitis B virus (HBV) infections. After being metabolized intracellularly to tenofovir diphosphate, it acts as a competitive inhibitor of the HIV reverse transcriptase enzyme and causes DNA chain termination, effectively halting viral replication. Tenofovir Disoproxil Fumarate is used in combination with other antiretroviral medications to treat HIV-1 and HIV-2 infections. It is effective in controlling viral replication and improving patient outcomes by reducing viral load.
Stability	Tenofovir is not a substrate, inducer, or inhibitor of human cytochrome P450 enzymes.
Brand name	Viread (Gilead Sciences).
Dosage	The standard recommended dosage for adults is 300 mg/day. In patients with significant renal impairment, the dosage must be adjusted to avoid accumulation of the drug and associated toxicities.

InChI:InChI=1/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1

202138-50-9 Relevant articles

Tenofovir Disoproxil Fumarate Clinical Pharmacology and Pharmacokinetics

Brian P. Kearney, John F. Flaherty & Jaymin Shah

Clinical Pharmacokinetics, Volume 43, pages 595–612, (2004)

The recommended oral dosage of tenofovir DF in adults is 300 mg/day. Tenofovir is eliminated by renal elimination, including tubular secretion; dose-interval adjustments are necessary for tenofovir DF in patients with significant renal impairment. No dosage adjustment of tenofovir DF is necessary in patients with liver disease.

Tenofovir Disoproxil Fumarate Clinical Pharmacology and Pharmacokinetics

Brian P. Kearney, John F. Flaherty & Jaymin Shah

Clinical Pharmacokinetics, Volume 43, pages 595–612, (2004)

Tenofovir exhibits longer serum (17 hours) and intracellular (≥60 hours) half-lives than those of nucleoside analogues, which supports a flexible once-daily administration schedule. The pharmacokinetics of tenofovir are dose-proportional and similar in healthy volunteers and HIV-infected individuals.

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

Nelson, Mark Ra; Katlama, Christineb; Montaner, Julio Sc; Cooper, David Ad; Gazzard, Briana; Clotet, Bonaventurae; Lazzarin, Adrianof; Schewe, Knudg; Lange, Joeph; Wyatt, Christinai; Curtis, Suej; Chen, Shan-Shanj; Smith, Stephenj; Bischofberger, Norbertj; Rooney, James Fj for the Tenofovir DF Expanded Access Team

AIDS 21(10):p 1273-1281, June 2007.

To characterize the safety profile of tenofovir disoproxil fumarate (DF) for the treatment of HIV infection in adults over the first 4 years of use.

202138-50-9 Upstream products

110-17-8
(2E)-but-2-enedioic acid
201341-05-1
tenofovir disoproxil
66224-66-6
adenine
14047-28-0
(R)-9-(2-hydroxypropyl)adenine

202138-50-9 Downstream products

1432630-26-6
9-[(R)-2-[[bis[[ (isopropoxycarbonyl)oxy]methoxy]phosphinyl]-methoxy]propyl]adenine fumarate Tenofovir disoproxil fumarate
201341-05-1
tenofovir disoproxil

Relevant Products

Fosfomycin tromethamine
CAS：78964-85-9
Lacosamide
CAS：175481-36-4
Olanzapine
CAS：132539-06-1

Product Class

202138-50-9

Product Details:

Buy High Quality Tenofovir Disoproxil Fumarate,Wholesale 202138-50-9 Safe Transportation

Tenofovir disoproxil fumarate(Cas 202138-50-9) Usage

202138-50-9 Relevant articles

Tenofovir Disoproxil Fumarate Clinical Pharmacology and Pharmacokinetics

Brian P. Kearney, John F. Flaherty & Jaymin Shah

Clinical Pharmacokinetics, Volume 43, pages 595–612, (2004)

Tenofovir Disoproxil Fumarate Clinical Pharmacology and Pharmacokinetics

Brian P. Kearney, John F. Flaherty & Jaymin Shah

Clinical Pharmacokinetics, Volume 43, pages 595–612, (2004)

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

AIDS 21(10):p 1273-1281, June 2007.

202138-50-9 Upstream products

202138-50-9 Downstream products

Relevant Products

Contact us

News Center

Site Map